Close menu




January 14th, 2020 | 10:54 CET

Ballard Power, dynaCERT, Tesla - the strength of innovations and solutions

  • Innovations
Photo credits: pixabay.com

On the capital market investors find an infinite variety of possibilities to invest their money. There are listed companies that have a history and are valued on the basis of compliance with prospects and fundamentals. And then there are innovative companies that attract capital regardless of all valuation parameters because they have a product that solves problems and arouses desires. If the product is also scalable, then the potential of the shares is often exorbitant, depending on the market size.

time to read: 1 minutes | Author: Mario Hose
ISIN: CA26780A1084 , CA0585861085 , US88160R1014

Table of contents:


    Ballard Power with hydrogen

    The Canadian fuel cell manufacturer Ballard Power has experienced a veritable price rally over the past 12 months. During this period, the company's share price rose from below EUR 2.80 to over EUR 9.50. The shareholders were able to achieve a return of over 230%.

    The market capitalization is now quoted at over 2 billion EUR. The topic of hydrogen in modern mobility is gaining more and more interest and based on that investors are looking for investment opportunities that are active in this field with scalable products.

    dynaCERT makes diesel greener

    Also located in Canada is the innovative company dynaCERT. After more than 15 years of research and development, the experts for hydrogen technologies were able to bring a device to series production readiness with which diesel engines can be retrofitted. The advantage of the technology is that the consumption of diesel can be reduced by up to 18% and, in addition, emissions of NOx, carbon dioxide and particulate matter are also significantly reduced.

    As currently circa one billion diesel engines are in operation and the use of dynaCERT's HydraGEN technology not only offers high savings in fuel consumption but also protects the environment, the share price could increase from below EUR 0.17 to over EUR 0.72 in the past 12 months. With a market value of EUR 230 million, the company is still a lightweight compared to Ballard Power.

    Tesla and the battery car

    Tesla from the USA is a prime example of a new trend. The manufacturer of battery cars has been the focus of reporting for over a decade. The founder at the top of the company is Elon Musk. He is driving Tesla's innovations forward and his announcements are causing euphoria and imagination on the capital market. It's hard to imagine that Tesla today would have a valuation of over EUR 81 billion if Tesla had been led by an employed CEO over the past ten years.

    Musk is there with passion and emotion, and this is the only way to keep the company continuously alive with new cash injections. The share price increased by over 60% from EUR 290.00 to EUR 475.00 in the comparison period. Ten years ago, Tesla shares changed hands at less than EUR 15.00, which clearly shows how enormous the potential of innovations and trends can be.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Nico Popp on September 18th, 2025 | 07:05 CEST

    Understanding metabolism, generating returns: Vidac Pharma, Roche, AstraZeneca

    • Biotechnology
    • Biotech
    • Pharma
    • Innovations
    • Cancer

    In the search for new treatments against diseases, researchers agree on one thing: the holy grail is unlikely to be found. Instead, it is incremental improvements and combination therapies that promise progress in complex diseases such as cancer. Cell metabolism is considered a promising approach, for example, in cancer, when the metabolism of a cancer cell is disrupted, the cell dies. In this article, we present current approaches and also discuss a biotechnology company that is wholly dedicated to cellular metabolism.

    Read

    Commented by Fabian Lorenz on September 16th, 2025 | 07:00 CEST

    Hot Stock shakes up Big Pharma! BioNxt Solutions aims to replace Ozempic weight loss injection!

    • Biotechnology
    • Pharma
    • Innovations
    • Investments

    BioNxt is currently shaking up Big Pharma. The announcement that it plans to replace the Ozempic weight loss injection with an oral dissolvable film is once again fueling speculation about the share price. Just like in the multiple sclerosis space, the Company aims to disrupt a billion-dollar obesity market. Further exciting operational news is expected in the coming months. Key patents are already in place. With a market capitalization of around CAD 100 million, the Canadian-German life sciences company is far from expensive – even for Big Pharma. The major corporations will undoubtedly be watching BioNxt's development very closely in the coming months. Until then, the stock is likely to trade significantly higher.

    Read

    Commented by Nico Popp on September 15th, 2025 | 07:15 CEST

    No more diet injections! Innovations in weight loss drugs: BioNxt Solutions, Merck & Co., Novo Nordisk

    • Biotechnology
    • Biotech
    • Pharma
    • Innovations

    As recently reported by the United Nations Children's Fund (UNICEF), for the first time, more children worldwide are obese than underweight. While this is a great success in the fight against hunger, it also poses new risks. Severe overweight in childhood leads to obesity and associated diseases in adulthood, such as cardiovascular problems and diabetes. The treatment of overweight and diabetes in children is therefore likely to play an even more significant role in the future. GLP-1 receptor agonists have been popular for several years now in the form of modern weight loss injections. With patents expiring soon, experts anticipate substantial further growth and development in this rapidly expanding market. We explain who could benefit and what the future holds for modern diet medications.

    Read